Loading
A phase 2 trial of Pixantrone, Ifosfamide, Etoposide and Rituximab in Non-Hodgkin lymphoma, run by The Lymphoma Academic Research Organisation, completed.
Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma is a phase 2 interventional study registered as NCT03458260 by The Lymphoma Academic Research Organisation, with 74 participants recorded, started 2018-12-26 and reaching its primary completion in 2024-12-24. Interventions recorded: Pixantrone, Ifosfamide, Etoposide, Rituximab, Transplant. Conditions recorded: Aggressive Non-Hodgkin Lymphoma.
Linked to the drug Pixantrone because the registry names it among its interventions and Non-Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pixantrone and the tag pipeline.
Shares Rituximab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Ifosfamide, Etoposide, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Rituximab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Ifosfamide and the tag pipeline.
Shares Rituximab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Etoposide and the tag pipeline.
Shares Rituximab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/